Advancing BBO-8520, a direct inhibitor targeting both the active (ON) and inactive (OFF) states of KRAS G12C, to overcome the limitations of first-generation OFF-state-only inhibitors.

Expected impact: Aims to address key mechanisms of adaptive resistance (such as KRAS G12C amplification and RTK activation) and provide a best-in-class therapeutic profile.

Developing BBO-11818, an orally bioavailable non-covalent pan-KRAS inhibitor designed to target multiple KRAS mutants (including G12D and G12V) in both ON and OFF states.

Expected impact: Addresses the high unmet medical need for patients with clinically significant KRAS mutations that lack approved targeted therapies.

Advancing BBO-10203, a first-in-class small molecule designed to block the physical interaction between RAS and PI3Kα, thereby inhibiting downstream PI3Kα/AKT signaling without causing hyperglycemia.

Expected impact: Provides a highly differentiated safety profile compared to traditional PI3Kα inhibitors by avoiding glucose metabolism disruption, enabling safe combination regimens.

Appointing Chief Scientific Officer Pedro J. Beltran, PhD, as Chief Executive Officer and board member Neil Kumar, PhD, as Executive Chairman to guide the company through its next phase of clinical expansion.

Expected impact: Designed to accelerate and focus the development of BBOT's clinical programs and move with urgency to deliver returns for patients and investors.